BNC210
Clinically significant anxiety disorders represent one of the most widespread health problems in the developed world. Historically, treatments for anxiety have been some of the most commercially successful products in the pharmaceutical industry. Annual sales of treatments for anxiety and related conditions are approximately US$12 billion.
However, current treatments suffer from many side effects including sedation, memory loss and addiction. Others are unsatisfactory for patients due to slow onset of action (weeks), or sexual dysfunction side-effects.
Bionomics has discovered a novel compound, BNC210, that offers dramatic competitive advantages over existing treatments. While providing excellent relief of anxiety in animal models, it shows no evidence of sedation, memory impairment or tendency to addiction. BNC210 has a rapid onset of action and is suitable for oral dosing.
BNC210 appears to act by a completely novel mechanism of action distinct from known drugs and may therefore represent the first in a new class of novel anxiety drugs offering dramatically improved patient benefits.
In June 2009, Bionomics initiated Phase 1 human clinical studies of BNC210 in healthy volunteers under the Therapeutic Goods Administration (TGA) Clinical Trial Notification (CTN) scheme.
In October 2009, BNC210 completed the first stage of the Phase I trial and is safe and well tolerated at doses that achieve drug blood levels consistent with suppression of the symptoms of anxiety in preclinical models.
